1 – 20 of 56
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort
(
- Contribution to journal › Article
- 2020
-
Mark
Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB
(
- Contribution to journal › Article
- 2016
-
Mark
Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections
(
- Contribution to journal › Article
-
Mark
Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
(
- Contribution to journal › Article
-
Mark
Validation of novel biomarkers for prostate cancer progression by the combination of bioinformatics, clinical and functional studies
(
- Contribution to journal › Article
- 2015
-
Mark
Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
(
- Contribution to journal › Article
- 2014
-
Mark
Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a In-111-radiolabelled monoclonal antibody, 11B6
(
- Contribution to journal › Article
-
Mark
Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens.
(
- Contribution to journal › Article
- 2013
-
Mark
Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens
(
- Contribution to journal › Article
-
Mark
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
(
- Contribution to journal › Article
- 2012
-
Mark
Quantification of cystatin C by time-resolved fluorometry-based immunoassays
(
- Contribution to journal › Article
-
Mark
Evaluation of a new immunoassay for cystatin C, based on a double monoclonal principle, in men with normal and impaired renal function
(
- Contribution to journal › Article
-
Mark
Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome
(
- Contribution to journal › Article
-
Mark
Targeting the human kallikrein-2 (hK2) expression in prostate cancer using 111In-labelled monoclonal antibody 11B6
2012) p.1102-1102(
- Contribution to conference › Abstract
-
Mark
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
(
- Contribution to journal › Article
-
Mark
Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations.
2012) In Journal of the National Cancer Institute(
- Contribution to journal › Article
- 2011
-
Mark
Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(145) or Lys(146) from fPSA without internal cleavages at Lys(145) or Lys(146)
(
- Contribution to journal › Article
-
Mark
A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without Screening
(
- Contribution to journal › Article
- 2010
-
Mark
Dry-Reagent Double-Monoclonal Assay for Cystatin C
(
- Contribution to journal › Article
-
Mark
Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication.
(
- Contribution to journal › Article